Company intelligence / Profile preview

TRx Biosciences

Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

TRx Biosciences has developed a proprietary oral delivery technology enabling targeted biodistribution of small molecules, enhancing absorption, tissue targeting (notably tumors and brain), and modifying immune responses. This approach shows promise in CNS, oncology, respiratory, and immune indications, and is supported by a strong IP portfolio.

Therapeutic areas: OncologyNeurologyImmunologyPulmonology
Modalities: Small moleculeOral drug delivery technology
Industry: Biotech

Partnerships

Not explicitly stated, but the company refers to a "proven track record in solving complex PK/PD limitations for lead clinical programs," implying external collaborations

Beyond the preview

Go deeper on TRx Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRx Biosciences.

Explore the full profile